Overview Dividends

(MRK) Merck - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58933Y1055

Oncology Vaccines Antimicrobials Diabetes Cardiovascular

Pharmaceuticals
Market Cap in USD: 247,306m
IPO / Inception: 1978-01-13
Return 12m vs S&P 500: -10.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of MRK over the last years for every Quarter: "2020-12": 1.32, "2021-03": 1.4, "2021-06": 1.31, "2021-09": 1.75, "2021-12": 1.8, "2022-03": 2.14, "2022-06": 1.87, "2022-09": 1.85, "2022-12": 1.62, "2023-03": 1.4, "2023-06": -2.06, "2023-09": 2.13, "2023-12": 0.03, "2024-03": 2.07, "2024-06": 2.28, "2024-09": 1.57, "2024-12": 1.72, "2025-03": 2.22, "2025-06": 2.13, "2025-09": 2.58,
EPS CAGR: 10.08%
EPS Trend: 13.5%
Last SUE: 3.25
Qual. Beats: 3

Revenue

Revenue of MRK over the last years for every Quarter: 2020-12: 12515, 2021-03: 10627, 2021-06: 11402, 2021-09: 13154, 2021-12: 13521, 2022-03: 15901, 2022-06: 14593, 2022-09: 14959, 2022-12: 13830, 2023-03: 14487, 2023-06: 15035, 2023-09: 15962, 2023-12: 14630, 2024-03: 15775, 2024-06: 16112, 2024-09: 16657, 2024-12: 15624, 2025-03: 15529, 2025-06: 15806, 2025-09: 17276,
Rev. CAGR: 6.75%
Rev. Trend: 70.3%
Last SUE: 0.60
Qual. Beats: 0

Dividends

Dividend Yield 3.24%
Yield on Cost 5y 5.08%
Yield CAGR 5y 5.91%
Payout Consistency 93.7%
Payout Ratio 37.9%
Risk via 5d forecast
Volatility 28.1%
Value at Risk 5%th 42.4%
Relative Tail Risk -8.14%
Reward TTM
Sharpe Ratio 0.23
Alpha -3.07
CAGR/Max DD -0.01
Character TTM
Hurst Exponent 0.447
Beta 0.377
Beta Downside 0.408
Drawdowns 3y
Max DD 43.44%
Mean DD 16.08%
Median DD 11.40%

Description: MRK Merck December 01, 2025

Merck & Co. (NYSE: MRK) is a global, diversified healthcare firm that markets prescription medicines (e.g., Keytruda, Januvia/Janumet, Gardasil), veterinary pharmaceuticals, and animal-health vaccines, while also maintaining a pipeline of oncology collaborations (Daiichi Sankyo ADCs, AstraZeneca Lynparza, LaNova LM-299) and partnership agreements with firms such as Eisai, Bayer and Moderna.

Key performance indicators from the most recent fiscal year show total revenue of roughly $13.5 billion, with Keytruda contributing about $5.5 billion (≈ 41 % of sales) and an R&D spend of $5.6 billion (≈ 41 % of revenue). The company’s dividend yield sits near 3 % and its cash-flow conversion remains above 80 %, while the broader pharma sector benefits from an aging global population and accelerating adoption of immuno-oncology therapies-both of which support Merck’s growth outlook.

For a deeper quantitative assessment, you may find ValueRay’s analyst tools useful.

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (19.03b TTM) > 0 and > 6% of Revenue (6% = 3.85b TTM)
FCFTA 0.10 (>2.0%) and ΔFCFTA -2.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 29.47% (prev 17.06%; Δ 12.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.13 (>3.0%) and CFO 17.07b <= Net Income 19.03b (YES >=105%, WARN >=100%)
Net Debt (23.20b) to EBITDA (27.57b) ratio: 0.84 <= 3.0 (WARN <= 3.5)
Current Ratio 1.66 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (2.50b) change vs 12m ago -1.69% (target <= -2.0% for YES)
Gross Margin 78.32% (prev 75.82%; Δ 2.50pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 52.00% (prev 53.75%; Δ -1.75pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 19.43 (EBITDA TTM 27.57b / Interest Expense TTM 1.18b) >= 6 (WARN >= 3)

Altman Z'' 4.96

(A) 0.15 = (Total Current Assets 47.56b - Total Current Liabilities 28.63b) / Total Assets 129.55b
(B) 0.56 = Retained Earnings (Balance) 72.23b / Total Assets 129.55b
(C) 0.19 = EBIT TTM 23.00b / Avg Total Assets 123.54b
(D) 0.89 = Book Value of Equity 68.82b / Total Liabilities 77.64b
Total Rating: 4.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 83.11

1. Piotroski 5.50pt
2. FCF Yield 4.82%
3. FCF Margin 20.31%
4. Debt/Equity 0.80
5. Debt/Ebitda 0.84
6. ROIC - WACC (= 16.52)%
7. RoE 38.95%
8. Rev. Trend 70.32%
9. EPS Trend 13.51%

What is the price of MRK shares?

As of December 20, 2025, the stock is trading at USD 101.09 with a total of 44,979,922 shares traded.
Over the past week, the price has changed by +1.65%, over one month by +7.26%, over three months by +25.08% and over the past year by +5.40%.

Is MRK a buy, sell or hold?

Merck has received a consensus analysts rating of 4.04. Therefore, it is recommended to buy MRK.
  • Strong Buy: 12
  • Buy: 3
  • Hold: 11
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MRK price?

Issuer Target Up/Down from current
Wallstreet Target Price 107.4 6.2%
Analysts Target Price 107.4 6.2%
ValueRay Target Price 104.4 3.3%

MRK Fundamental Data Overview December 13, 2025

Market Cap USD = 247.31b (247.31b USD * 1.0 USD.USD)
P/E Trailing = 12.9256
P/E Forward = 10.5374
P/S = 3.85
P/B = 4.7395
P/EG = 1.0429
Beta = 0.299
Revenue TTM = 64.23b USD
EBIT TTM = 23.00b USD
EBITDA TTM = 27.57b USD
Long Term Debt = 39.97b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 41.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.20b USD (from netDebt column, last quarter)
Enterprise Value = 270.51b USD (247.31b + Debt 41.37b - CCE 18.17b)
Interest Coverage Ratio = 19.43 (Ebit TTM 23.00b / Interest Expense TTM 1.18b)
FCF Yield = 4.82% (FCF TTM 13.05b / Enterprise Value 270.51b)
FCF Margin = 20.31% (FCF TTM 13.05b / Revenue TTM 64.23b)
Net Margin = 29.63% (Net Income TTM 19.03b / Revenue TTM 64.23b)
Gross Margin = 78.32% ((Revenue TTM 64.23b - Cost of Revenue TTM 13.93b) / Revenue TTM)
Gross Margin QoQ = 81.92% (prev 77.50%)
Tobins Q-Ratio = 2.09 (Enterprise Value 270.51b / Total Assets 129.55b)
Interest Expense / Debt = 0.58% (Interest Expense 238.0m / Debt 41.37b)
Taxrate = 14.20% (958.0m / 6.75b)
NOPAT = 19.73b (EBIT 23.00b * (1 - 14.20%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.85b)
Debt / EBITDA = 0.84 (Net Debt 23.20b / EBITDA 27.57b)
Debt / FCF = 1.78 (Net Debt 23.20b / FCF TTM 13.05b)
Total Stockholder Equity = 48.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 14.69% (Net Income 19.03b / Total Assets 129.55b)
RoE = 38.95% (Net Income TTM 19.03b / Total Stockholder Equity 48.87b)
RoCE = 25.89% (EBIT 23.00b / Capital Employed (Equity 48.87b + L.T.Debt 39.97b))
RoIC = 22.93% (NOPAT 19.73b / Invested Capital 86.06b)
WACC = 6.41% (E(247.31b)/V(288.68b) * Re(7.40%) + D(41.37b)/V(288.68b) * Rd(0.58%) * (1-Tc(0.14)))
Discount Rate = 7.40% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 78.94% ; FCFE base≈13.77b ; Y1≈14.41b ; Y5≈16.75b
Fair Price DCF = 118.4 (DCF Value 293.77b / Shares Outstanding 2.48b; 5y FCF grow 5.00% → 3.0% )
EPS Correlation: 13.51 | EPS CAGR: 10.08% | SUE: 3.25 | # QB: 3
Revenue Correlation: 70.32 | Revenue CAGR: 6.75% | SUE: 0.60 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.64 | Chg30d=-0.498 | Revisions Net=-2 | Analysts=7
EPS next Year (2026-12-31): EPS=8.59 | Chg30d=-0.797 | Revisions Net=-7 | Growth EPS=-4.2% | Growth Revenue=+5.3%

Additional Sources for MRK Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle